In the IMMUNOTARGET study, in which NSCLC patients with oncogenic driving alterations were treated with ICIs in the second and subsequent lines, patients with RET-altered NSCLC achieved median overall survival (mOS) 21.3 months (3.8; 28.0 mo) and mPFS 2.1 months (1.3; 4.7 mo). This evidence concerns the gene RET and non-small cell lung carcinoma.